Acute Aortic Syndrome
12
4
4
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
The EnvScore-Aorte Diagnostic Study Protocol for the Identification of Acute Aortic Syndrome
Additive Anti-inflammatory Action for Aortopathy & Arteriopathy
Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)
Protective Effect of Ulinastatin Against Negative Inflammatory Response and Organ Dysfunction After Acute Type a Aortic Dissection Surgery (PANDA I)
Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)
VOCs in Patients With Acute Cardiogenic Chest Pain
Evaluation of the Castor Single Branch Stent Graft in Treatment of Acute Aortic Syndrome
Integrated Diagnostic Algorithm for Acute Aortic Syndromes
Genetic Profile in Patients With Aortic Syndrome
18F Sodium Fluoride PET/CT in Acute Aortic Syndrome
French National Observatory of Aortic Syndromes
Is a Pre-contrast Scan Necesary to Diagnose Acute Aortic Syndrome?